Spyre Announces Potential Best-In-Class Spy003 (Anti-Il-23) Part A Induction Results From Skyline Trial, Completing Proof-Of-Concept For All Three Components Of Its Ibd Combinations
SYRE•Skyline trial induction results
Sept. 8 (Reuters) - Spyre Therapeutics Inc. SYRE.O:
- Spyre announces potential best-in-class Spy003 (anti-IL-23) Part A induction results from Skyline trial, completing proof-of-concept for all three components of its IBD combinations
- Spyre Therapeutics - Spy003 meets primary endpoint with 10.0-point RHI reduction at week 12
- Spyre Therapeutics - Spy003 achieves 20% clinical remission and 30% endoscopic improvement at week 12
- Spyre Therapeutics - Skyline Part B enrolling; topline induction data expected in 2027
- Spyre Therapeutics - Spy003 well tolerated with safety profile consistent with IL-23 class
